About Strategia

Strategia Team

More than 200 years of collective experience in the pharmaceutical industry

Together with our global partners, our core team is highly experienced, and has specific expertise in a diverse range of pharmaceutical development areas, from biochemistry and drug development to life-cycle management and pharmaceutical business strategy.

Keizo Koya, PhD, Founder, President and CEO

Keizo Koya, PhD

Dr. Keizo Koya is a dynamic leader, senior executive, and entrepreneur with three decades of experience in global pharmaceutical R&D and business strategy. In 2012, he formed Strategia Therapeutics, Inc. to implement his visionary new model for collaborative drug development, and established global pharmaceutical R&D alliances with partners such as M.D. Anderson Cancer Center, Fujifilm, Eisai, Nippon Shinyaku, and Insymbiosis. Prior to founding Strategia Therapeutics, Dr. Koya worked for Synta Pharmaceuticals (SNTA) for 10 years as Senior Vice President of Drug Development, where he helped discover and develop novel pharmaceutical drugs like “Apilomod” (a first-in-class oral active IL12/23 inhibitor for autoimmune and inflammatory diseases), “Ganetespib”, (a powerful Hsp90 inhibitor), and “Elesclomol”, a cancer metabolism inhibitor for oncology. Prior to joining Synta, Dr. Koya led R&D for numerous investigational cancer and autoimmune drugs at Shionogi BioResearch Corp, Fuji ImmunoPharmaceuticals Corporation, and FujiFilm USA. He also led the anti-cancer drug project at Harvard Medical School’s Dana Farber Cancer Institute, developing innovative cancer mitochondria-targeted therapies (such as MKT-077), later licensed to Sandoz (Novartis). Before moving to the U.S. in 1990, Dr. Koya worked as a chief scientist for various projects at FujiFilm Japan’s main research institute. He holds a Ph.D. in organic chemistry, and has 45 issued and pending U.S. patents.

Back to Top

Linda Paradiso, DVM, MBA, Chief Operating Officer

Linda Paradiso, DVM, MBA

Dr. Linda Paradiso has more than 32 years of oncology drug development experience in pharmaceutical and emerging biotechnology research. She has dozens of investigational new drugs (INDs) to her credit, and has contributed directly to the worldwide development, approval and lifecycle management of 11 marketed anti-infective and oncology therapeutics (Viracept®, Penetrex®, Omnicef®, Doxil®, DepoCyt®, Treanda® Kepivance®, Neulasta®, Aranesp®, Vectibix® and NPlate®). She has served at an executive management level in multiple clinical and regulatory executive management positions at companies, including Tanox (now Genentech), Amgen, Pfizer, Agouron (now Pfizer) and Salmedix (now Cephalon/TEVA).

Dr. Paradiso is a former Officer of several publicly traded biotechnology companies, and is a former Director of Amgen. She has served on the Commercialization and Scientific Review Board of the Texas Emerging Technology Fund, and the Associate Advisory Board of BioHouston. Over the course of her career, she has helped procure more than $30 million dollars in venture and corporate capital funds for emerging biotechnology, and has participated in numerous licensing deals between large pharmaceutical firms and budding biotech companies. Dr. Paradiso received her DVM from Michigan State University, and earned an MBA with emphasis in Health Care Management from University of California, Irvine. She received her undergraduate BS degrees from the University of Michigan.

Back to Top

Thomas Myers, MD, FACP, Chief Medical Officer

Thomas Myers, MD, FACP

Thomas J. Myers is a board certified hematologist and oncologist with 38 years of clinical and pharmaceutical experience. His career has included 23 years on the faculty at the Brown University Affiliated Hospitals and 15 years in oncology medical affairs and clinical drug development at four pharmaceutical companies. Dr. Myers has extensive clinical drug development experience consisting of more than 250 U.S. and global investigator-sponsored and company-sponsored trials, 40 U.S. and E.U. cooperative group trials, four cooperative research and development agreements with the National Cancer Institute (NCI), seven expanded access programs, one global registry, and the development and supervision of investigator-sponsored and cooperative group trial programs at three companies. He has been involved in the launch of six hematology and oncology agents. Dr. Myers has served in multiple prior pharmaceutical positions: Assistant Medical Director, Oncology at Ortho Biotech (Johnson & Johnson); Medical Director, Oncology, Global Medical Affairs at Millennium Pharmaceuticals; Sr. Medical Director and Acting VP, Oncology, Global Medical Affairs at Genzyme Pharmaceuticals; and VP Oncology, US Development and Medical, EMD Serono (a subsidiary of Merck Serono). He is a Fellow of the American College of Physicians, a Fellow of the International Academy of Clinical and Applied Thrombosis and Hemostasis, and the recipient of the Brown University 20-year outstanding teacher award.

Back to Top

Donald P. Andrade, CPA, Chief Financial Officer

Donald P. Andrade, CPA

Donald P. Andrade assists companies develop and implement their growth strategies, focusing on financial matters. He has over 30 years of experience providing advice to a broad spectrum of companies, from early-stage to mature global entities. Prior to forming his advisory firm, Mr. Andrade was a partner at Deloitte & Touche LLP where his tenure spanned 28 years. He has authored publications on the topics of raising capital and global growth strategies.

Mr. Andrade is a frequent speaker on various topics including raising capital, financial reporting (U.S. GAAP, IFRS) and regulatory developments, and is an adjunct faculty member at Boston University, Suffolk University and the University of Alabama Law School. He earned a BS in BA from Bryant University, Summa Cum Laude, and is a Certified Public Accountant.

Back to Top

Louis DePalatis, PhD, Senior Director, Translational Medicine

Louis DePalatis, PhD

Dr. Louis DePalatis has over 32 years of experience in research and development of pharmaceuticals, imaging agents and medical devices. He began his career in the Bioproducts division of the Dow Chemical Company where he conducted research on cell growth control mechanisms and established preclinical experimental models to evaluate monoclonal antibodies (Mabs) and small molecules for precision tumor targeting applications. His efforts contributed to initiation of clinical studies to evaluate the imaging and therapeutic properties of radioimmunoconjugates in cancer patients. Additionally, he provided pharmacology and regulatory support for clinical development of a novel drug for treatment of electrolyte imbalance. At Navidea (formerly Neoprobe) Corp. and Wendt-Bristol Diagnostics, Dr. DePalatis was responsible for coordination of translational studies with device manufacturers and surgeons to co-develop radioimmunoconjugates and medical devices for surgical resection of tumor metastases. As a Director at MD Anderson Cancer Center (MDACC), his key responsibilities included: grant mentorship; advising faculty on design and execution of research projects for molecular targeting and imaging applications, and; solicitation and management of collaborative research initiatives with industry.

Dr. DePalatis is a member of 3 scientific organizations, is on the scientific advisory board of Enlyton, LLC, and served on MDACC advisory committees. He is co-author on 30 research publications and has delivered over 50 technical presentations at professional conferences. He earned his PhD from The Ohio State University, his MS from Southern Illinois University and his BS from Slippery Rock University.

Back to Top

Mary Johansen, PharmD, Senior Director, Regulatory Affairs and Quality Assurance

Mary Johansen, PharmD

Dr. Johansen has worked in the field of oncology pharmacotherapeutics and drug development for the past 25 years, and is a recognized expert in pharmacokinetics, pharmacodynamics and drug metabolism.  She has more than 20 years of broad experience in investigational new drug (IND) development for a range of therapeutic strategies, including small molecules, biologics, and conjugates of botanical extracts and antibody drugs. She has also been involved the development and monitoring of pharmacologically-guided Phase I trials for anticancer agents. She now leads the regulatory affairs operations for Strategia Therapeutics, and has facilitated the movement of several projects through regulatory review by the FDA. These capabilities allow for secure electronic regulatory submissions to be routed through the central transmission gateway to the FDA, thereby reducing resource requirements and improving time and cost efficiencies for both the sponsors and the Agency.

Dr. Johansen received her post-doctoral residency and research fellowship training at the University of Texas M. D. Anderson Cancer Center (MDACC), and became faculty in 1995. As a founding scientist and Co-Director of the Pharmaceutical Development Center at MDACC, she led numerous novel anticancer therapies from early preclinical stages to Phase I investigation.  Dr. Johansen also served as Co-Director of the Core Pharmacology and Analytical Facility at MDACC, focusing on the development of chromatographic and mass spectrometry methodology to support preclinical and clinical pharmacology, pharmacokinetic, and toxicokinetic investigations in addition to chemistry, manufacturing and control support for new agent development.  Through extensive leadership experience in these fields, she brings a broad base of expertise in the design, management, and regulatory oversight of IND-directed pharmacokinetic and toxicology studies.

Back to Top

David S. Wages, MD, PhD, Medical Director

David S. Wages, MD, PhD

Dr. David Wages has been developing novel drugs and devices for the past twenty years. After receiving his M.D. and Ph.D. in cancer biology at University of Virginia, David completed a laboratory medicine residency at UCSF and then a fellowship in hematopathology at Beth Israel-Deaconess Hospital. David then joined Cerus Corporation in California where his work spanned pre-clinical research to registration trials for blood decontamination systems. David then moved on to positions in large Pharma and CROs (Wyeth, EMD Serono and Quintiles) as well as other small biotech companies (Ariad and iSpecimen). While David enjoyed a brief stint helping investors at the Health-focused investment bank Leerink-Swann; he prefers to develop products and services. After the focus on hematology at Cerus and Wyeth, Dr. Wages has spent the last ten years concentrating on cancer therapeutics for both solid and hematologic malignancies. He has designed and directed single country and global Phase 1 through Phase 3 trials for cytotoxics, biologics, immuno-oncology products and targeted small molecules.

Back to Top

Michele Rosner, MS, Director, Clinical Operations & Drug Safety

Michele Rosner, MS

Michele Rosner has been involved in pharmaceutical research and development for more than 20 years, and has strong expertise in clinical operations including project oversight, protocol development, timeline management, data collection, document creation, report generation, and results presentation. Ms. Rosner began her pharmaceutical research career at Pfizer Corporation in 1993 as a Scientist in the Protein Chemistry Group, Exploratory Medical Sciences, where she evaluated protein drug targets from recombinant and naturally occurring sources for biophysical properties. In 2003, she became Lead Project Manager in the Safety Narrative Group, Safety Risk Management, where she was responsible for safety narrative project planning, implementation and serious adverse event narrative writing for global regulatory submissions of pre-market programs, as well as post-market indications. After 14 years at Pfizer, she joined Repros Therapeutics as Clinical Program Director, where she was responsible for building the clinical operations group and managing clinical trials for reproductive health and breast cancer therapies. In this capacity, she was responsible for protocol development and writing, clinical site selection, qualification, study initiation and monitoring, CRO selection and management, database review and study timeline management for Phase 1-3 programs in reproductive health and breast cancer.

Over the course of her career, Ms. Rosner has gained special expertise in building relationships with key opinion leaders, establishing and organizing Data Safety Monitoring Boards, and interacting with the FDA. She received her BS degree in Chemistry from William Smith College, her MS in biological chemistry from Rensselaer Polytechnic Institute, and her MS in Management from Albertus Magnus College, New Haven, CT. In addition to her professional experience, she has also served as an adjunct chemistry instructor in the Department of Health, Kinesiology and Natural Science at Lone Star College in Tomball, TX.

Back to Top

Teletha Gipson, MS, PhD, Director, Clinical Operations

Teletha Gipson, MS, PhD

Teletha Gipson has more than 22 years of drug development experience in Pharma, Biotech and Start-up companies. She has a broad experience with global, multi-disciplinary drug development teams, and has usher drugs like Neurontin®, Femhrt®, and Estrostep® through successful regulatory filings and approvals. Dr. Gipson has experience in Oncology, Neurosciences, Respiratory, Endocrinology, Ophthalmology, Women’s Health Care, Infectious Diseases, HIV, and Cardiovascular therapeutic areas. She joined Parke-Davis/Warner-Lambert in 1993, holding positions of increasing responsibility in clinical trial support (clinical pathology, toxicology, immunotoxicology), project leadership, and laboratory operations. She has served in multiple management level positions, including Senior Scientist and Study Director, Parker Davis/Warner Lambert (now Pfizer); Associate Director, Global Project Management, She also has experience in providing quality assurance and compliance support for development and manufacturing teams.

Dr. Gipson has in-depth knowledge and expertise in portfolio and clinical/project management in small and large organizations, and has managed drug candidates from early through advanced phases of development in a diverse, matrixed environment at Pfizer Global R&D and Tanox. This includes serving as alliance manager, and chairing several committees for inter-company partnerships/alliances. Dr. Gipson earned her Ph.D. degree from Meharry Medical College and a Master of Science from Texas Southern University, and holds a B.S. degree from University of Houston.

Back to Top

Akinori Hishiya, PhD, Director, Biology

Akinori Hishiya, PhD

Dr. Hishiya is responsible for technology development at Strategia Therapeutics. His primary role is to organize and lead Strategia’s teams in creating new technologies to support patient needs. He has in-depth knowledge and expertise in the field of molecular and cellular biology, and has researched a diverse range of diseases including osteoporosis, muscular atrophy, neurodegenerative disease, cardiovascular disease, and cancer. Dr. Hishiya’s most recent development, TapBoost™, offers a unique and promising way to control intracellular protein folding machineries specific to a target protein. The technology holds the potential to enhance productivity of therapeutic recombinant proteins, and to cure many conformational diseases such as cystic fibrosis. Dr. Hishiya received his Ph.D degree in 2006 from Tohoku University (Japan) and completed postdoctoral studies at Medical College of Georgia and Boston Biomedical Research Institute. He has been published in many prestigious scientific journals, and holds several patents and patent applications. He has been a featured speaker at scientific conferences around the globe.

Back to Top

Luke Lawson, PhD, Director, Quality Assurance

Luke Lawson, PhD

Luke Lawson has more than 20 years’ experience serving regulated industry in engineering, project management, clinical development. process validation, regulatory and quality operations capacities. Luke has a history of leveraging his comprehensive understanding of standards and regulations to creatively design and implement right-sized solutions for pharmaceutical. biotech, CRO and medical device companies.  He has a demonstrated history of designing and evaluating business solutions, vendor offerings, and programs that improve performance, productivity and profitability. He also brings experience interacting with global regulatory authorities and has an array of regulatory submissions to his credit.  Luke brings a disciplined approach to adequately defining problems so that the resulting solutions fully address them.

Luke also understands the importance of service and is active in a number of areas. He is the current President of the Tarleton Alumni Association and a member of the Engineering Advisory Board at Tarleton; as well as a member of the Biomedical Engineering Advisory Board at the University of North Texas.

Back to Top

Jay Thapar, BS, Manager, Pharmaceutical Information

Jay Thapar, BS

Jay Thapar has spent that last 15 years working in the field of drug development. For 10 years at the MD Anderson cancer center he was responsible for DMPK and CMC equipment operation, sample tracking and analysis, providing training of new employees in analytical methodology, as well as IT functions supporting the department. More recently, Jay was the director of operations at a start-drug development company where he was involved in all phases of preclinical and clinical drug development, including protocol preparation, timelines, budgets and creation of a Laboratory Management Information System (LIMS) using Visio Studio, and was responsible for all IT management. Additionally, Jay has developed various custom software packages for data management, project management and laboratory supply management.

Jay has a vast working knowledge of many commonly used equipment used in bioanalytical services, including liquid chromatograph and mass spectrometry software, raw electronic data backup and archiving, systems and server administrator for third party software, customized interactive web-based software project tracking systems, and IT support. Additionally, he has extensive training experience and expertise in analytical laboratory techniques and storage of electronic data. Jay holds a BS in Chemistry from Sam Houston State University.

Back to Top

Nana Law, MBA, Administrative Manager

Nana Law, MBA

Nana Law believes that administration is the backbone of any business operation. Since 2013, she has served as administrative manager for Strategia Therapeutics, playing a multi-faceted role as Strategia’s point person for human resources, information technology, payroll, accounting, legal matters, general & front office management and other business operations. With management and communication skills in both Japanese and English—as well as an MBA—she provides strong facilitation for Strategia. In carrying out her responsibility as Strategia’s Administrative Manager, her goal is to ensure that administrative function is strategically aligned with all other business functions and supports all Strategia team members solidly.  Prior to joining Strategia, Ms. Law was a travel consultant at IACE Travel in Boston. She received her BS in Human Science from Waseda University in Japan, and her MBA from Southern New Hampshire University.  Ms. Law continues to accumulate her global management skills as she gains a deeper understanding of both Japanese and American cultures.

Back to Top